Baidu
map

JAHA:慢性肾脏疾病脓毒症幸存者长期心血管事件风险如何?

2017-02-15 xing.T MedSci原创

该研究结果突出了在慢性肾脏病幸存者中脓毒症与显著增加的长期心血管事件风险相关。

慢性肾脏病患者发生脓毒症后长期心血管预后尚未有研究报道。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章。研究人员旨在探讨台湾慢性肾脏病患者因脓毒症住院治疗出院后发生心血管事件的风险。

研究人员采用来自于台湾国家健康保险研究数据库中的慢性肾脏病患者完整的索赔数据为基础,确定了在2000年至2010年期间住院的脓毒症幸存患者。每一个脓毒症幸存者通过倾向性评分匹配的一个非脓毒症住院患者作为对照者。研究人员采用Cox回归模型估计临床结局的风险比,包括主要不良心血管事件(心肌梗死、缺血性脑卒中)、因心力衰竭住院治疗情况以及所有原因的死亡。

在66961例脓毒症的幸存者中,所有原因的死亡和主要心血管不良事件在研究期间的发生率分别为288.51和47.05每1000人每年。与匹配的住院非脓毒症对照患者相比,脓毒症幸存者发生主要不良心血管事件(风险比为1.42;95%可信区间为1.37-1.47)、心肌梗死(风险比为1.39;95%可信区间为1.32-1.47)、缺血性卒中(风险比为1.46;95%可信区间为1.40-1.52)、因心衰而住院(风险比为1.55;95%可信区间为1.51-1.59)和全因死亡率(风险比为1.56;95%可信区间为1.54-1.58)的风险更高。在患者的几个亚组分析中结果仍然保持不变,并在死亡竞争风险的分析中结果也相似。

由此可见,该研究结果突出了在慢性肾脏病幸存者中脓毒症与显著增加的长期心血管事件风险相关。

原始出处:


Chia‐Jen Shih,et al. Long‐Term Risk of Cardiovascular Events in Patients With Chronic Kidney Disease Who Have Survived Sepsis: A Nationwide Cohort Study. JAHA.2017. https://doi.org/10.1161/JAHA.116.004613

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643441, encodeId=1cad164344140, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 28 08:40:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176813, encodeId=02691e68131b, content=深度好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:42:31 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267389, encodeId=2420126e3896a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287625, encodeId=3888128e6259d, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616094, encodeId=cf37161609415, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643441, encodeId=1cad164344140, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 28 08:40:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176813, encodeId=02691e68131b, content=深度好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:42:31 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267389, encodeId=2420126e3896a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287625, encodeId=3888128e6259d, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616094, encodeId=cf37161609415, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=)]
    2017-02-18 1ddf0692m34(暂无匿称)

    深度好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1643441, encodeId=1cad164344140, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 28 08:40:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176813, encodeId=02691e68131b, content=深度好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:42:31 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267389, encodeId=2420126e3896a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287625, encodeId=3888128e6259d, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616094, encodeId=cf37161609415, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=)]
    2017-02-17 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643441, encodeId=1cad164344140, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 28 08:40:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176813, encodeId=02691e68131b, content=深度好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:42:31 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267389, encodeId=2420126e3896a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287625, encodeId=3888128e6259d, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616094, encodeId=cf37161609415, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643441, encodeId=1cad164344140, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Jul 28 08:40:00 CST 2017, time=2017-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=176813, encodeId=02691e68131b, content=深度好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Feb 18 13:42:31 CST 2017, time=2017-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267389, encodeId=2420126e3896a, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287625, encodeId=3888128e6259d, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616094, encodeId=cf37161609415, content=<a href='/topic/show?id=9c95536521c' target=_blank style='color:#2F92EE;'>#慢性肾脏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53652, encryptionId=9c95536521c, topicName=慢性肾脏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=305019728622, createdName=12498b08m96暂无昵称, createdTime=Fri Feb 17 00:40:00 CST 2017, time=2017-02-17, status=1, ipAttribution=)]

相关资讯

Diabetes Care:抑郁症让糖尿病患者的慢性肾脏疾病风险增加?

背景:伴抑郁症的糖尿病患者,其慢性肾脏疾病(CKD)风险是否会增加?我们对美国糖尿病退伍军人进行了研究,探究抑郁症和CKD发生率、心血管事件发生率和死亡率之间的联系。 方法:本项全国性前瞻性队列研究从超过300万美国退伍军人(基线估计肾小球滤过率(eGFR)≥60 mL/min/1.73 m2)中识别了933211例糖尿病患者。根据ICD-9-CM编码诊断糖尿病,HbA1c >6.4%

Am J Kidney Dis:多读书可降低慢性肾疾病患者死亡风险?

研究者对慢性肾脏疾病(CKD)患者进行了一项研究,探究患者的最高教育程度和患者血管事件风险、肾脏疾病进展和病因特异性死亡率间的联系。该前瞻性研究纳入了SHARP研究中的参与者,涉及9270名中到重度CKD成年患者,其中6245名患者基线时候没有接受透析治疗,所有来自欧洲、北美、亚洲、澳大利亚和新西兰的参与者没有心肌梗死或冠状动脉血运重建的既往史。研究组根据参与者的教育程度将其从无正规教育到高等教育

JACC:PCI和CABG治疗慢性肾脏疾病,长期和短期结果有差异

经皮冠状动脉介入治疗(PCI) vs 冠状动脉旁路移植术(CABG)的随机试验通常排除了患有慢性肾脏病(CKD)的患者。该研究的目的是评估CKD患者进行PCI vs CABG的结果。在纽约,该研究的参与者包括那些使用依维莫司洗脱支架接受PCI的CKD患者,以及倾向得分匹配的那些接受隔离CABG治疗多支冠状动脉病变的患者。主要研究终点为全因死亡率。次要终点是心肌梗死(MI),卒中和再次血运重建。在1

Am J Kidney Dis: 慢性肾病患者,心血管预后存在种族差异

背景:患有终末期肾脏疾病的非西班牙裔黑人和西班牙裔人比非西班牙裔白人死亡风险增加,但在非透析依赖性慢性肾脏病患者中,心血管预后的种族差异的数据有限。研究设计:前瞻性队列研究。设置和参与者:3785例肾小球滤过率为20-70ml/min/ 1.73m2进入CRIC(慢性肾功能不全的队列)研究。设置:种族(非西班牙裔白人,非西班牙裔黑人和西班牙裔人)。预后:心血管疾病(动脉粥样硬化事件[心肌梗死、卒中

JAMA Int Med:南方医科大学新研究——叶酸可以减缓慢性肾脏病进展

目前,叶酸治疗对于肾功能的疗效还没有在未进行叶酸强化的人群中进行调查。

AIM:美国慢性肾脏疾病患病率在近十年趋于稳定

背景和目的:对于卫生保健政策和规划而言,慢性肾脏疾病(CKD)患病率的趋势是非常重要的。研究者通过重复横断面研究对CKD的患病趋势进行了更新。方法:纳入1988-1994年的NHANES(全国健康和营养检查调查),从1999到2012年,每2年一次。参与者为年满20岁或以上的成年人。慢性肾脏病(3和4期)被定义为eGFR为15-59mL/min/1.73 m2。CKD的扩展的定义还包括eGFR≥6

Baidu
map
Baidu
map
Baidu
map